



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 30000

Title: THE FUTURE OF LIVER DISEASE IN THE ERA OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C

Reviewer’s code: 00503345

Reviewer’s country: Canada

Science editor: Yuan Qi

Date sent for review: 2016-09-03 20:06

Date reviewed: 2016-09-10 05:29

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this manuscript the authors review the rapidly growing clinical information of the impact of new direct acting antivirals on hepatitis C virus clearance and infection eradication. The efficacy of these antiviral treatments on fibrosis and HCV- related liver diseases such as cirrhosis and increased risk hepatocellular carcinoma are discussed. The potential benefits in term of economic burden associated with patient’s death and number liver transplantations due to organ failure are estimated.

General Comments: Overall the review is well written and almost comprehensive. Major points.

1. The three tables are not easy reading as presented. More compact tables would help. 2. A table listing all the direct acting antivirals cited in the review and their targets should be included. 3. Although the potential impact of the new direct acting antivirals is well discussed, it is not clear whether these regimens will reduce the risk of resistance to anti-HCV therapies. To my knowledge resistances to new direct acting antivirals have been reported and this should be briefly discussed.

Minor points. A list of abbreviations would be useful since some abbreviations are not defined immediately after the first use in the text. Please define SIM as simprevir in the manuscript.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 30000

Title: THE FUTURE OF LIVER DISEASE IN THE ERA OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C

Reviewer's code: 03648382

Reviewer's country: United States

Science editor: Yuan Qi

Date sent for review: 2016-09-03 20:06

Date reviewed: 2016-10-03 22:54

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

This review is summarized on the impact of HCV eradication and DAAs on HCV infection related liver disease. An overall evaluation was an extensive and good article. However the tables were not very clear. Tables should be simplified. In addition more emphasis should be made high costs and resistance about DAAs.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 30000

Title: THE FUTURE OF LIVER DISEASE IN THE ERA OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C

Reviewer's code: 00006518

Reviewer's country: Taiwan

Science editor: Yuan Qi

Date sent for review: 2016-09-03 20:06

Date reviewed: 2016-09-28 15:37

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Comments: 1. Concerning the authorship in a review article (usually very small in numbers) and judged from 'author contributions' stated by the authors, please clarify the role of the rest authors other than Ponziani FR, Mangiola F, and Binda C. 2. Spell-check (such as 'reviewed literature' instead of 'reviexed literature' in 'Author Contribution' and lowercase for 'Countries' in 'Abstract', format for references, etc.) and grammar-check (for a better readability) needed. 3. Cautious citation for proper references suggested, e.g. reference 24 is a 'letter to editor' (for reference 25) instead of an 'original article', reference 36 has nothing to do with DAAs, reference 70 is a review paper but not an original article addressing the incidence of HCC being reduced by HCV viral clearance as the author mentioned paper (published in 1995), Veldt et al.'s article is reference 47 not 49, reference 56 is a review article which did not address specifically on molecular mechanisms on liver fibrosis after HCV being cleared by DAAs, etc. 4. Take care of the reference style for WJG (to add PMID or not?). 5. The authors need to clarify more clearly for the final two sentences in 'IMPACT OF VIRAL ERADICATION ON LIVER FIBROSIS' (references 60-67 and 56) for better readability and



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

understanding. 6. Duplicate sentence "This finding is associated with...during antiviral treatment with DAAs." in 'IMPACT OF VIRAL ERADICATION ON THE DEVELOPMENT OF HCC'. 7. Correct abbreviation for simeprevir to 'SMV' under '2. DAAs treatment after liver transplantation' section. 8. Please reorganized 'CONCLUSION' to a better & concise form, and avoid too many 'nevertheless' in its current version.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 30000

Title: THE FUTURE OF LIVER DISEASE IN THE ERA OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C

Reviewer's code: 02462179

Reviewer's country: China

Science editor: Yuan Qi

Date sent for review: 2016-09-03 20:06

Date reviewed: 2016-09-28 20:14

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this study, the authors summarized the basic information of direct acting antivirals and the impact of HCV eradication on liver cirrhosis, fibrosis, hepatocellular carcinoma. They also described the associations of direct acting antivirals and liver transplantation. Finally, the future prospect of HCV infection and HCV-related complication was demonstrated in the end of the article. The topic was interesting. However, the basic information of direct acting antivirals should be summarized in tables or figures. They are more concise and easy to read. Moreover, how about the drug resistance in the process of antiviral treatment? Furthermore, professional are needed to correct the English of manuscript.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 30000

Title: THE FUTURE OF LIVER DISEASE IN THE ERA OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C

Reviewer's code: 03020633

Reviewer's country: China

Science editor: Yuan Qi

Date sent for review: 2016-09-03 20:06

Date reviewed: 2016-09-26 16:18

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

This review is comprehensive on the impact of HCV eradication or SVR on HCV infection related liver disease, such as liver fibrosis, liver cirrhosis decompensation, HCC and liver transplantation. While, I think that the content of effect antiviral therapy by IFN+RBV treatment on liver disease was a little lengthy and should be compressed. The content about DAA on HCV related liver disease is well reviewed and very readable. Due to the high cost, DAA may be only applicable in developed countries in the near future. There is a long way to go to assess DAA on situations of HCV infection globally.